Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

152.97 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 152.97
Bid (Size) 116.93 (1)
Ask (Size) 243.22 (1)
Prev. Close 152.97
Today's Range 152.97 - 152.97
52wk Range 119.59 - 153.07
Shares Outstanding 122,180,759
Dividend Yield 1.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
Via Benzinga

Performance

YTD
+8.63%
+8.63%
1 Month
+3.81%
+3.81%
3 Month
+7.83%
+7.83%
6 Month
+20.71%
+20.71%
1 Year
+15.55%
+15.55%

More News

Read More
Uncovering Dividend Opportunities with NYSE:DGX.
Via Chartmill
5 Analysts Assess Quest Diagnostics: What You Need To Know
Via Benzinga
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Via Benzinga
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Via Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
The Analyst Landscape: 5 Takes On Quest Diagnostics
Via Benzinga
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Via MarketBeat
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Via Benzinga
Topics Cannabis
Exposures Cannabis
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Via Talk Markets
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.